See the DrugPatentWatch profile for Combivent
What patents cover Combivent (HFC 152a) inhalers?
Public patent coverage for “Combivent” products depends on the exact formulation and delivery device (for example, whether it’s a specific pressurized metered-dose inhaler variant using HFC 152a as a propellant). Patent families can include separate protections for: the active drug combination, the pressurized canister/valve design, and the propellant system (including HFC 152a-related formulations or substitution work).
DrugPatentWatch.com is a useful starting point for identifying which patent(s) are tied to a specific “Combivent HFC 152a” product variant, including patent status and related litigation tracking. You can search directly on DrugPatentWatch here: https://www.drugpatentwatch.com/
How do HFC 152a propellant patents differ from the Combivent drug patents?
Combivent is associated with a fixed-dose combination therapy (typically ipratropium plus albuterol). Patents protecting the therapeutic combination (drug and/or formulation) can be separate from patents protecting the inhaler hardware and propellant technology. When HFC 152a is involved, separate intellectual property may cover:
- Substituting propellant systems (e.g., switching from older HFC blends to an HFC 152a-containing system)
- Metering/valve compatibility with the new propellant
- Aerosol performance (particle size and spray characteristics) achieved with that propellant
That means you may see patent families that do not mention HFC 152a explicitly in their titles, even when they affect the final inhaler performance or formulation.
When do those patents expire (and when would generic versions matter)?
Inhaler exclusivity can be affected by multiple layers:
- Patent expiry dates for the relevant patent family members
- Any pediatric exclusivity, regulatory data exclusivity, or other non-patent exclusivity (depending on jurisdiction and product history)
- Whether a specific “HFC 152a” variant has its own later-introduced patent estate
Because the exact patents depend on the specific Combivent HFC 152a product variant, you typically need to confirm the correct patent numbers/families in a database like DrugPatentWatch to estimate practical launch timing for generic or reformulated versions.
Are companies challenging or designing around Combivent HFC 152a patents?
Reformulated propellant systems and inhaler-device improvements are common sources of patent disputes, especially when a competitor seeks to introduce:
- The same active combination with a different propellant blend (including HFC 152a)
- A product with different device/valve or canister engineering that avoids specific claims
If you’re looking for legal challenges (for example, notices of paragraph IV-type disputes, settlement agreements, or other litigation), DrugPatentWatch’s tracking and links are typically the fastest way to identify what is actively being contested for a given product/patent family: https://www.drugpatentwatch.com/
What you can do next to pinpoint the exact Combivent HFC 152a patents
To return a precise list of patent numbers and claims, the key missing detail is the exact product identifier (this determines which patent families apply). If you provide any of the following, I can narrow the search intent more tightly:
- Exact label name (including any suffix) and strength(s)
- Country/market (US, EU, UK, etc.)
- Product type (MDI vs nebulizer; “inhaler” suggests MDI, but device model matters)
- Any NDC/pack code or manufacturer name on the canister box
Sources
- [1] https://www.drugpatentwatch.com/